Kala Pharmaceuticals (KALA) Misses Q3 EPS by 6c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 5, 2020 7:00 AM EST
-- Obtained FDA Approval for EYSUVISTM, First Prescription Therapy Approved Specifically for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease --
-- EYSUVIS Expected to Begin Shipping to Wholesalers by End of 2020 --
-- 3Q 2020 INVELTYS® Net Revenue of $2.2 Million --
-- Cash Position and INVELTYS Revenue Expected to Provide Runway Into at Least 3Q 2022
EYSUVIS Revenue Expected to Provide Additional Runway --
-- Conference Call and Webcast at 8:00 a.m. ET --
WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ:... More
